Laborie Medical Technologies Corp. (Laborie), a leading diagnostic and therapeutic medical technology company, has launched alpHaONE, a wireless pH-capsule reflux testing system designed to diagnose gastroesophageal reflux disease (GERD). GERD is a chronic medical condition that causes the flow of contents from the stomach upwards into the esophagus, leading to symptoms and complications. It is estimated that 20% of the US population suffers from GERD, with heartburn and regurgitation being the most common symptoms.
The alpHaONE system offers up to 96 hours of monitoring data, making it a unique and desirable solution for GERD diagnosis. With several options available for GERD diagnosis, patients and healthcare providers face a challenge in selecting the best solution for a clear diagnosis. The alpHaONE system solves this problem with its ergonomic and compact design, enlarged and easy-to-press buttons, and a fail-safe capsule delivery system that protects the patient’s esophagus.
Also Read:
“alpHaONE is a patient-centric system that allows for comfortable monitoring and accurate, reliable data, fulfilling the needs of both patients and healthcare providers to diagnose GERD,” said Rhett Klein, Vice President of Sales and Marketing for Laborie’s GI Business Unit. “Our primary objective has always been to provide solutions that elevate patient outcomes and enhance their overall experience, and we look forward to launching this product.”
The comprehensive software application in the alpHaONE system consists of a Virtual Instruction Program, which allows for effortless navigation. Additionally, user-customizable symptom buttons and automatic pH data analysis ensure a seamless user experience. The launch of alpHaONE further expands Laborie’s Gastroenterology Motility and Reflux Portfolio and their commitment to advancing diagnostic solutions for esophageal diseases.
Also Read:
Laborie will showcase alpHaONE at the Digestive Disease Week (DDW) event in Chicago, Illinois on May 6-9, 2023. The event is an annual meeting that brings together healthcare professionals, researchers, and industry stakeholders to discuss the latest advances in digestive diseases, including GERD.
Laborie Medical Technologies is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology, and Neonatal Health. The company manufactures and delivers high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Clinicians and hospitals consider Laborie as the market-leading experts in their business segments, and the company supports its products with a world-class Clinical Education & Information program.
Also Read:
Laborie is owned by Patricia Industries, a part of Investor AB, and is headquartered in Portsmouth, New Hampshire. Patricia Industries is a long-term owner that invests in companies and works to develop each company to its full potential. Investor AB, founded by the Wallenberg family in 1916, is an engaged owner of high-quality, global companies. Through board participation, industrial experience, their network, and financial strength, Investor AB works continuously to support their portfolio companies to remain or become best-in-class.
Overall, the launch of alpHaONE is a significant milestone for Laborie Medical Technologies, and it represents their continued commitment to improving patient outcomes and providing innovative medical technologies to diagnose esophageal diseases. With up to 96 hours of monitoring data, alpHaONE will offer a unique and valuable solution for GERD diagnosis.
Also Read:
In Other News Around the World: